{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
alpha-tocopherol acetate
to a specific field?
Status:
Investigational
Source:
NCT02944383: Phase 2 Interventional Completed Severe Hypertriglyceridemia
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Gemcabene calcium (PD 72953), the monocalcium salt of a dialkyl ether dicarboxylic acid, is a lipid-regulating compound that was first described in 1998. It down-regulates apolipoprotein C-III expression, enhancing the clearance of very low density lipoprotein (LDL), and reduces plasma triglycerides. It also raises high-density lipoprotein cholesterol (HDL). Unlike fibrates (blood trygliceride level lowering drugs), its mechanism of action is not linked to agonist or antagonist activity on PPAR-α receptors. There is limited information on the exact mechanism of action, but an anti-inflammatory profile was found, associated with a lowered expression of the high-sensitivity C-reactive protein gene regulating mechanisms. Gemcabene (administered as 6, 6’-oxybis [2, 2-dimethyl-4-hexanoic acid] monocalcium salt) has been investigated for treatment in a wide range of hyperlipidaemias, as well as atherosclerosis, and cardiovascular disorders. Gemcabene is generally well tolerated. One phase 2 study testing the preliminary efficacy and safety of gemcabene in children with established nonalcoholic fatty liver disease has been stopped early due to increasing weight and a rise in liver fat content in patients. Clinical trials are still ongoing.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Tibalosin is a phenylethylamine derivative patented by Continental Pharma as a potent vasodilator. Tibalosine interacts specifically with alpha- and beta-adrenergic receptors and calcium channel binding sites. In preclinical models, Tibalosin exerts favor influences on arterial pressure in the hypertensive animal. The drug has acceptable toxicity in experimental animals and has been well tolerated by normal human subjects in daily doses of up to 200 mg.
Class (Stereo):
CHEMICAL (ACHIRAL)
Tiodazosin is a newly developed antihypertensive agent, structurally related to prazosin. Prazosin and tiodazosin administrated intravenously to anesthetized rats, are equally effective hypotensive agents, but that the hypotensive potency of prazosin is greater than that of tiodazosin. However, chronic administration of equivalent doses of the two compounds for 25 and 52 days via the drinking water indicated approximately equivalent, sustained reductions in blood pressure. Furthermore, at the end of the 52-day chronic dosing period tiodazosin caused appreciably less alpha-adrenergic receptor antagonist activity than prazosin as assessed by the norepinephrine dose-pressor response profiles.
Status:
Investigational
Source:
NCT00570752: Phase 2 Interventional Completed Vascular Diseases
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
BMS-582949 acts as a dual action kinase inhibitor. It inhibits both p38 mitogen-activated protein kinase (p38 MAPK) activity and activation of p38. As a blocking agent for activation of p38 kinase BMS-582949 appeared to be well suited to resist such cellular responses that would drive p38 activation more strongly. BMS-582949 is in Phase II clinical trials for the treatment of rheumatoid arthritis, psoriasis, and atherosclerosis.
Status:
Investigational
Source:
NCT00169559: Phase 2 Interventional Completed Dyslipidaemias
(2003)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
GW 590735 is a selective and potent agonist of peroxisome proliferator-activated receptor alpha (PPARα), a ligand-activated transcription factor that plays a key role in lipid homeostasis. Activation of PPARα results in increased clearance of triglyceride (TG) rich very low-density lipoprotein. GW 590735 was in phase II clinical trial for the treatment of dyslipidemia, but that study was discontinued.
Class (Stereo):
CHEMICAL (ACHIRAL)
Besunide was studied as a diuretic agent.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Etiracetam is a nootropic agent. (-)-(S) enantiomer of etiracetam levetiracetam (Keppra®) is used for the treatment of epilepsy.
Class (Stereo):
CHEMICAL (ACHIRAL)
Pipradimadol is a 4.4-disubstituted piperidine derivative which demonstrates, in animal experiments, effects typical for certain antidepressant and antiserotonin drugs. Pipradimadol is the central serotonin antagonist. Pipradimadol exhibits antinociceptive properties also. Behavioral tests reflect overall sedation after pipradimadol, decreased rectal temperature and locomotor activity; cataleptic effects of tetrabenazine are antagonized and noradrenaline as well as dopamine reuptake in vitro are slightly inhibited. Homovanillic acid, a metabolite of dopamine is strongly increased after pipradimadol in rat striatum. Pipradimadol was used as analgesic agent.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Piriprost (U-60, 257) is a structural analog of prostaglandin I2 (PGI2) with low IP receptor-mediated activity. It inhibits 5-LO (5-lipoxygenase). Piriprost inhibits the release of histamine and leukotrienes, implicating its role in inflammation and allergic responses. However, it was shown, that piriprost did not influence the airway responses after allergen in asthma. Nevertheless, even more, the drug was irritant to the respiratory tract than was placebo.
Status:
Investigational
Source:
NCT00084812: Phase 1 Interventional Completed Unspecified Adult Solid Tumor, Protocol Specific
(2004)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Safingol, the synthetic L-threo-stereoisomer of endogenous (D-erythro-) sphinganine, is an inhibitor of protein kinase C and sphingosine kinase in vitro, and in some cell types has been implicated in ceramide generation and induction of apoptosis. Safingol inhibits enzymatic activity and 3H-phorbol dibutyrate binding of purified rat brain PKC (IC50 = 37.5 uM and 31uM, respectively). Inhibits human PKCα, the major overexpressed isoenzyme in MCF-7 DOXR cells (IC50 = 40 uM). Safingol enhances the cytotoxic effect of the chemotherapeutic agent Mitomycin C (MMC) in gastric cancer cells by promoting drug-induced apoptosis. Safingol is an inhibitor of SphK (Sphingosine kinase). Safingol has been shown to act synergistically with other chemotherapeutic agents and may potentiate chemotherapy drug-induced apoptosis in vitro and in vivo.
